Feedback PLC TexRAD Prostate Cancer Product Development (0651B)
05 Oktober 2015 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 0651B
Feedback PLC
05 October 2015
Feedback plc
("Feedback" or the "Company")
Intention to develop a product incorporating TexRAD for prostate
cancer
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce the incorporation of a 50:50 joint venture
company, Prostate Checker Ltd, ("PC") with QUIBIM S.L.,("QUIBIM")
to develop a specific application of TexRAD texture analysis in
combination with multiple extracted parameters from MR images for
the computer assisted detection and diagnosis of prostate cancer.
To facilitate this, Feedback Plc has granted a licence of certain
TexRAD intellectual property to PC.
QUIBIM, which is based in Valencia, Spain, derives its name from
Quantitative Imaging Biomarkers In Medicine. It has collaborative
relationships with Spanish hospitals and is especially dedicated to
medical image processing and the extraction of imaging biomarkers
for medical imaging workflows. Prostate Checker will combine
texture analysis with other image analysis parameters from QUIBIM
such as diffusion and perfusion to develop an integrated product
which would potentially assist clinicians in diagnosing and
assessing treatment options for prostate cancer. The potential
implications for patient care are very significant, with the
additional information to be derived from PC's analysis of
routinely acquired MR images allowing for better risk
stratification of patients and more personalised treatment. A
presentation is available on http://prostatechecker.co.uk .
A preliminary study undertaken at the University College London
of around 100 prostate cancer patients demonstrated the potential
for TexRAD analysis of MR images to differentiate between
significant and less significant cancers. This was presented at the
International Society of Magnetic Resonance in Medicine (ISMRM) in
Milan in 2014.
Prof. Dr. Luis Martí-Bonmatí, a leading European radiologist and
authority on the use of MRI in diagnosing abdominal and pelvic
cancers, commented:
"TexRAD MR texture analysis in combination with QUIBIM diffusion
& perfusion modelling may be a useful tool for risk
stratification to identify patients with significant cancers from
less significant prostate cancers and more accurately triaging
those prostate cancer patients for appropriate management
(treatment or active surveillance)"
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer
of the Company's subsidiaries TexRAD Ltd & Cambridge Computed
Imaging Ltd commented:
"We are delighted to be setting up a joint venture company
Prostate Checker Ltd, with QUIBIM to develop a composite imaging
risk stratification multi-parametric (textures, perfusion,
diffusion etc) MR software product dedicated to the management of
prostate cancer patients."
Dr. Angel Alberich-Bayarri, Chief Executive Officer of QUIBIM
commented:
"We are very pleased in starting this new strategic alliance
with Feedback, where our high performance teams will merge under
the umbrella of the new JV company, Prostate Checker Ltd. I am sure
that we can develop the most advanced MR imaging solutions for
prostate cancer diagnosis in the market which wouldn't be possible
with independent strategies".
For further information contact:
Feedback plc Tel: 01954 718072
Simon Barrell / Trevor Brown / Tom
Charlton
QUIBIM SL Tel: +34 6867
84484
Angel Alberich-Bayarri
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Ltd Tel: 020 7469
(Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
is readily visible to the naked eye. Research to date has shown
that TexRAD could potentially assist the clinician (as an 'Imaging
Biomarker') in confident decision-making: it has the potential to
assess the prognosis, disease-severity (e.g. risk of metastases)
and response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'. TexRAD is
manufactured under licence by company Cambridge Computed Imaging
Ltd, a subsidiary of Feedback plc. More information is available on
www.fbk.com and www.texrad.com.
QUIBIM is a company specialized in the analysis of imaging
biomarkers from medical images. The company receives the images
from the customer, performs the image analysis and provides back an
intuitive report with the relevant results for the diagnosis,
prognosis and staging of lesions. Therefore the qualitative
approach of radiology is complemented by QUIBIM's quantitative
service. The company is currently developing a new platform
(QUIBIM-Precision(R)) under the philosophy of SaaS (software as a
service) that will allow the analysis of a spectrum of imaging
biomarkers that can be extracted from medical images (magnetic
resonance, computed tomography, positron emission tomography,
X-ray) in different organs and pathologies ('from head to toe'
approach). The main solutions of the company beyond the prostate
are their advanced analysis of trabecular bone from MR or CT for
the microarchitecture characterization in osteoporosis and
oncology; the liver fat fraction and iron concentrations
quantification; the lung emphysema quantification in COPD
(Patented) and neuroimaging techniques (volumetry, morphometry,
tractography, lesions detection, iron concentration) for brain
diseases diagnosis. More information is available at
www.quibim.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFFIIFLFIIE
(END) Dow Jones Newswires
October 05, 2015 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024